532321

- Zydus Lifesciences Limited incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, on August 25, 2026. - The 'Gift City Company' in Gandhinagar, Gujarat, will undertake global/regional corporate treasury activities and services. - The subsidiary is 100% owned with a paid-up share capital of Rs. 5 Crores.

- CRISIL Ratings assigned Zydus Lifesciences an overall ESG Score of 66 for FY 2025-2026. - The previous score was 61, indicating an improvement. - CRISIL considers a score between 61-70 as 'strong'.

- Mr. Prashant Babubhai Patel, Member of the Promoter Group, received 32,577 equity shares via transmission from Late Jasodaben Babubhai Patel, also a Member of the Promoter Group. The off-market transaction occurred on August 19, 2026.

- Zydus Lifesciences Ltd submitted its investor presentation for a conference on August 24-26, 2026. The presentation highlights strong financial performance with FY26 Revenue of INR 2,71,484 Mn, EBITDA of INR 84,751 Mn (31.2% margin), and PAT of INR 54,564 Mn (20.1% margin), reflecting consistent growth and a diversified global portfolio.

- Zydus Lifesciences Limited received an overall ESG rating of 60 from ESGRAIL, a SEBI registered ESG Rating Provider. - The company stated that it had not engaged ESGRAIL for this independent rating, which was based on publicly available information.

- Zydus Lifesciences received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP. - The product has been designated as a Competitive Generic Therapy (CGT), granting 180-day exclusivity. - The brand product had annual sales of approximately USD 11.6 million in the United States as per IQVIA MAT June-2026. - The product will be manufactured at the company's USFDA-approved injectable plant in Jarod, Gujarat, and marketed in the US.

- Commenced FY27 with strong double-digit growth, registering consolidated revenues of ₹80.2 billion (▲22% YoY) and an EBITDA margin of 24.1%. Net profit for Q1 FY27 was ₹9.4 billion. - India branded formulations business grew 20% YoY, outpacing market; mid-teens growth expected for FY27. - International markets formulations business posted revenues of ₹9.7 billion (▲34% YoY); North America business revenues were ₹31 billion (▲5% QoQ). - Consumer Wellness business recorded revenues of ₹14.3 billion (▲67% YoY), with double-digit growth expected for FY27. - Maintained guidance for strong double-digit revenue growth and 24%+ EBITDA margin for FY27, with long-term target of 28-30% EBITDA margin within 5 years. - FY27 Capex is guided around ₹1,500-₹1,600 crores for facility expansion and R&D initiatives. - Key strategic initiatives include the launch of Nufymco™ (first US biosimilar), acquisition of Assertio Holdings, and progress on Saroglitazar Magnesium NDA (USFDA priority review, FY28 launch with $200-$400+ million potential). - Significant R&D pipeline advancements across biosimilars, vaccines, and NCEs, including Phase III trials for Desidustat (sickle cell disease) and a second ADC Biosimilar. - Planned 30-40 US product launches for FY27, with US branded business expected to contribute over 15% of US revenue by year-end.

- Zydus Lifesciences management will meet investors in Singapore and Hong Kong for a Non-Deal Roadshow (NDR). - The investor conference is scheduled from August 24 to August 26, 2026.

- Zydus Lifesciences Limited's participation in the Motilal Oswal 22nd Annual Global Investor Conference, 2026, has been rescheduled. - The conference will now be held on August 17, 2026, instead of August 18, 2026.

- Zydus Lifesciences Limited announced voting results of its 31st Annual General Meeting held on August 11, 2026. - All resolutions were passed, including the adoption of financial statements, declaration of a final dividend of ₹1/- per equity share, and re-appointments of directors.

- Re-appointment of Dr. Sharvil P. Patel as Managing Director for a further five years (April 1, 2027 to March 31, 2032). - Appointment of Mr. Kulin S. Lalbhai as an Independent Director for a term of five years (May 19, 2026 to May 18, 2031). - Both resolutions were passed at the 31st Annual General Meeting held on August 11, 2026.